Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• Diagnosis of painful bladder syndrome/interstitial cystitis

• Moderate or severe bladder pain

Exclusion Criteria:

• Any other uncontrolled disease

• Pregnant or nursing females